Overdose with digoxin has conventionally been treated by supportive measures aimed at inhibiting the absorption of the drug and counteracting its cardiac effects. More recently, impressive success has been documented using digoxin-specific Fab antibodies for the treatment of life-threatening digoxin toxicity.
CASE REPORT A 65-year-old woman with a past history of rheumatic fever and analgesic nephropathy was admitted following suicidal ingestion of seventy 0.0625 mg tablets of digoxin (4.375 mg) five hours earlier. Her usual medications included digoxin 0.0625 mg daily. Initial treatment included insertion of an intravenous line gastric lavage and charcoal instillation via ~ nasogastric tube. Her serum potassium was 4.3 mmolll (normal range 3.9-4.5 mmolll). Serum creatinine was 395 J..ImollI. Serum digoxin level was 19.8 nmollI. On admission, blood pressure was 135/85 and heart rate was 130/min and irregular. She was alert but complained of blurred vision and nausea. She vomited on repeated occasions. The electrocardiograph (ECG) showed atrial and junctional tachycardia with intermittent 2: 1 to 4: 1 block, and occasional ventricular ectopic beats. Several hours later serum potassium had risen to 5.0 mmollI. She was admitted to the Intensive Care Unit.
Phenytoin 500 mg was administered intravenously slowly, with no effect. Repeat serum biochemistry showed that serum potassium had risen further to 5.4 mmollI. Vital signs were unchanged. Following a test dose, 600 mg digoxin-specific Fab fragments were administered slowly intravenously over half an hour. The ECG remained unchanged. One hour later, a further 400 mg of digoxinspecific Fab fragments were given intravenously, and one hour following the second dose the ECG showed sinus rhythm at 110 beats/min and the serum potassium had returned to 4.5 mmollI. The patient remained in sinus rhythm and the heart rate slowed over the next four hours to 90/min. She was discharged from Intensive Care the following day and remained in hospital for a further four days because of an incidental ear infection. No free digoxin was detectable in the serum twenty minutes after the first dose of digoxin-specific Fab fragments and after precipitation of the circulating digoxin antibody from the serum specimen with anti-sheep goat antibody (Burroughs Wellcome).
DISCUSSION

In this patient with moderate renal
Anaesthesia and Intensive Care, Vol. 15 insufficiency and serum digoxin level of 19.8 nmol/l, the use of digoxin-specific Fab fragments reversed symptoms and signs of digoxin toxicity and allowed a rapid discharge from intensive care and hospital. Given a serum creatinine of 400 {.imol/l and serum digoxin level of 19.8 nmol/l, the estimated time for the serum digoxin level to fall to a level of 2.5 nmol/l is approximately three weeks. With invasive interventions such as haemodialysis and charcoal haemoperfusion, this time is not significantly shortened. ECG changes of digoxin intoxication are diverse and virtually all types of arrhythmia and conduction disturbances have been described.
Hyperkalaemia may occur in cases of severe toxicity, due to profound inhibition of sodium potassium ATPase. 1 Indeed, greater serum potassium concentrations are associated with the poorest prognosis 2 and can be extremely refractory to conventional management. 3 Potential risk of digoxin toxicity can be determined by assessment of cardiac arrhythmias and the serum potassium concentration. High risk patients such as those with accelerated nodal rhythm, severe ventricular arrhythmias, high grade atrioventricular block with bradycardia, and paroxysmal atrial tachycardia with block, should be monitored in an intensive care unit, as should those with a serum potassium greater than 5.0 mmol/l and those with serum digoxin levels greater than 5.0 nmol/I.
In the majority of circumstances, patients with digoxin toxicity respond to conventional measures. Hypokalaemia should be carefully corrected, although with massive overdose the level of serum potassium may rise dangerously high. 3 Atropine and temporary pacing may be required. Antiarrhythmic drugs are used for cases with enhanced automaticity. Phenytoin has had widespread use, but atrial tachycardia with block and atrioventricular junctional tachycardia do not respond readily. 4 Lignocaine has also been used with success. Beta blockers are considered hazardous, however, in view of their cardiovascular depression and negative chronotropic effect. DC shock may precipitate resistant ventricular fibrillation.
Oral activated charcoal, along with cholestipol and cholestyramine, will increase the clearance of digoxin, especially in patients with renal impairment. 5 However, their use in advanced toxicity is limited because of the time required for their effect. Vomiting may also red uce their efficiency. Similarly, haemodialysis and haemoperfusion techniques are relatively ineffective because of the very large volume of distribution and high degree of tissue binding by digoxin. While control of hyperkalaemia may be achievable with dialysis, the total amount of digoxin removed has been reported to be less than 1070. 6 Butler and Chen suggested the use of digoxin-specific antibodies in 1967. 7 Smith et al. and others have documented great success using digoxin antibodies in vitro, in animals 8 -1O and more recently in humans.II-14 Smith and coworkers have succeeded in purifying the digoxin-specific antibody, and have used the cleaved Fab fragment to treat life-threatening digoxin toxicity. The Fab fragment is preferred because it is much less immunogenic than the parent immunoglobulin. The Fab fragment also undergoes more rapid and extensive distribution to the extravascular compartment and has more rapid renal excretion than does IgG.13 Reversal of the toxic effect of digoxin overdose with digoxin-specific antibody is rapid. Our patient reverted to sinus rhythm with a fall in serum potassium within one hour of the infusion. Spiegal 15 has reported that following cessation of the Fab fragment infusion, gastro-intestinal toxicity reversed immediately, while cardiac rhythm (bradyarrhythmias) and potassium disturbances corrected after 30-60 minutes. Tachyarrhythmias may take longer to respond, and intervals of up to four hours are reported. 16 So rapidly and effectively is hyperkalaemia reversed by Fab fragment infusion that aggressive conventional treatments for hyperkalaemia are not necessary. Smith 3 has identified criteria for appropriate candidates for immunological reversal of digoxin toxicity.
These are: 1. advanced and potential life-threatening toxicity, 2. when conventional therapies have failed, or the toxic exposure is judged to be so great that conventional therapy is considered likely to fail, and 3. the exclusion of immediate hypersensitivity with skin testing or a small test dose. While the patient in this report had an arrhythmia (atrial tachycardia with a variable degree of 2: 1-4: 1 block) it was not in itself lifethreatening at the time of treatment. However, the variable nature of the block was considered an ominous sign. Accordingly, and in view of the serum digoxin level of 19.8 nmol/l, the presence of moderate renal insufficiency and the rising serum potassium, the use of digoxinspecific Fab fragments was considered justified and a prolonged hospital stay was avoided.
While the results of digoxin-specific Fab fragment treatment for digoxin toxicity have so far been impressive, there are potential problems associated with it. The possibility of immunogenic reactions, either immediate hypersensitivity or serum sickness, remains, although so far neither has been reported. The cost is significant, being $110 for 40 mg in Australia and supplies are limited to the major capital cities. Other potential problems include the difficulty in measuring serum digoxin concentration, especially in the face of a therapeutic necessity to continue digoxin therapy.
